India Pharma Outlook Team | Wednesday, 07 October 2026
India’s biopharma today gathers real momentum as peptides and antibody-drug conjugates reshape the sector.
Private companies pour capital into complex molecules, academic labs create sharper diagnostic tools, and state governments build AI innovation hubs.
These moves mark a clear pivot from high-volume generics toward higher-margin advanced therapeutics and precision health technologies.
Private CapEx, and research breakthroughs now reinforce one another and strengthen India’s position in the global value chain for oncology, peptide manufacturing and smart diagnostics.
Aragen Life Sciences has operationalized Aragen OneHP, an integrated development and manufacturing platform for peptides and antibody-drug conjugates at its Nacharam campus in Hyderabad.
The platform adds capacity for highly potent molecules, including cytotoxic payloads used in oncology, and includes one active-ingredient manufacturing line with an annual capacity of 500–600 kg. Over the past three years the company has invested more than Rs 1,000 crore to build capabilities across small molecules and biologics.
In FY26 Aragen reported operating revenue of Rs 2,178 crore, adjusted EBITDA of Rs 593 crore and net profit of Rs 283 crore. The CRDMO now operates three small-molecule facilities with a combined capacity of 364 KL and a biologics site in Bengaluru.
Granules India has planned an investment of about Rs 2,000 crore over the next three to four years. The capital will support complex generics, oncology, peptide contract development and manufacturing, US operations, R&D infrastructure, digitalization, AI-led manufacturing excellence and quality systems.
The company has returned to growth in FY26 after nearly three years of flat performance. Complex generics already account for 33 percent of revenue in FY26, up from just 1 percent in FY20, and form 45–50 percent of finished-dosage revenue.
Granules positions its peptide CDMO platform, built around Senn Chemicals, to reach profitability in FY27, a USD 50 million annual revenue run rate in three years and more than USD 100 million within five years.
Key growth engines the company highlights include:
Also Read: Why Vaccine Innovation Must Go Beyond Traditional Platforms
Researchers at the Indian Institute of Science Education and Research, Berhampur, have developed a nanotechnology-based fluorescent sensor that enables faster detection and stratification of diabetic kidney disease using urine samples.
The COF-based fluorescent immunosensor detects the protein NGAL and distinguishes diabetic kidney disease samples from other clinical groups. The team notes that overlapping clinical features often make differentiation from other kidney disorders difficult.
The sensor offers a rapid, minimally invasive biomarker based approach. While it does not yet replace established diagnostic methods, it provides a promising platform for further optimization and clinical validation.
Private investment in peptides, ADCs and oncology, academic advances in precision diagnostics and state-level AI and deep-tech policy now work in tandem. India is deliberately shifting from volume-driven generics toward high-complexity, higher-margin biopharma and precision health technologies. The combination of CapEx, research output and enabling policy positions the country as a stronger global player in advanced therapeutics and diagnostics.
.jpg)
